XBiotech Inc. (XBIT): Price and Financial Metrics

XBiotech Inc. (XBIT): $3.05

-0.05 (-1.61%)

POWR Rating

Component Grades













Add XBIT to Watchlist
Sign Up

Industry: Biotech



in industry


  • Value is the dimension where XBIT ranks best; there it ranks ahead of 58.11% of US stocks.
  • XBIT's strongest trending metric is Growth; it's been moving up over the last 169 days.
  • XBIT ranks lowest in Momentum; there it ranks in the 5th percentile.

XBIT Stock Summary

  • The ratio of debt to operating expenses for XBIOTECH INC is higher than it is for about only 0.51% of US stocks.
  • Equity multiplier, or assets relative to shareholders' equity, comes in at 1.03 for XBIOTECH INC; that's greater than it is for merely 5.84% of US stocks.
  • Revenue growth over the past 12 months for XBIOTECH INC comes in at -57.16%, a number that bests just 3.19% of the US stocks we're tracking.
  • If you're looking for stocks that are quantitatively similar to XBIOTECH INC, a group of peers worth examining would be PTGX, RNA, CRSP, NRIX, and ENTA.
  • XBIT's SEC filings can be seen here. And to visit XBIOTECH INC's official web site, go to www.xbiotech.com.

XBIT Valuation Summary

  • In comparison to the median Healthcare stock, XBIT's price/earnings ratio is 111.64% lower, now standing at -2.7.
  • Over the past 93 months, XBIT's EV/EBIT ratio has gone up 34.5.

Below are key valuation metrics over time for XBIT.

Stock Date P/S P/B P/E EV/EBIT
XBIT 2022-11-25 11.8 0.4 -2.7 3.2
XBIT 2022-11-23 12.0 0.4 -2.7 3.1
XBIT 2022-11-22 12.1 0.4 -2.8 3.1
XBIT 2022-11-21 12.3 0.4 -2.8 3.1
XBIT 2022-11-18 12.6 0.4 -2.9 3.0
XBIT 2022-11-17 12.9 0.4 -2.9 3.0

XBIT Growth Metrics

    Its 5 year net income to common stockholders growth rate is now at 1378.37%.
  • Its 4 year cash and equivalents growth rate is now at 603.71%.
  • Its 4 year net income to common stockholders growth rate is now at 1378.37%.
XBIT's revenue has moved down $27,956,000 over the prior 18 months.

The table below shows XBIT's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-09-30 8.21 -19.286 -36.164
2022-06-30 11.049 -16.661 -26.767
2022-03-31 14.044 62.513 -20.241
2021-12-31 18.394 69.445 -17.414
2021-09-30 19.163 70.813 -12.785
2021-06-30 25.193 81.698 -12.05

XBIT's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • XBIT has a Quality Grade of D, ranking ahead of 11.91% of graded US stocks.
  • XBIT's asset turnover comes in at 0.071 -- ranking 289th of 682 Pharmaceutical Products stocks.
  • QLGN, GTHX, and CPHI are the stocks whose asset turnover ratios are most correlated with XBIT.

The table below shows XBIT's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.071 0.391 -0.195
2021-03-31 0.102 0.248 -0.138
2020-12-31 0.124 0.215 -0.116
2020-09-30 0.082 0.166 7.794
2020-06-30 0.070 0.188 10.040
2020-03-31 0.039 0.237 14.665

XBIT Stock Price Chart Interactive Chart >

Price chart for XBIT

XBIT Price/Volume Stats

Current price $3.05 52-week high $13.12
Prev. close $3.10 52-week low $3.00
Day low $3.05 Volume 22,000
Day high $3.19 Avg. volume 75,092
50-day MA $3.55 Dividend yield N/A
200-day MA $5.87 Market Cap 92.84M

XBiotech Inc. (XBIT) Company Bio

XBiotech Inc. is a clinical-stage biopharmaceutical company, engages in discovering and developing “True Human™” monoclonal antibodies for treating various different diseases. The company was founded in 2005 and is based in Austin, Texas.

XBIT Latest News Stream

Event/Time News Detail
Loading, please wait...

XBIT Latest Social Stream

Loading social stream, please wait...

View Full XBIT Social Stream

Latest XBIT News From Around the Web

Below are the latest news stories about XBIOTECH INC that investors may wish to consider to help them evaluate XBIT as an investment opportunity.

XBiotech Third Quarter 2022 Earnings: US$0.42 loss per share (vs US$0.11 loss in 3Q 2021)

XBiotech ( NASDAQ:XBIT ) Third Quarter 2022 Results Key Financial Results Net loss: US$12.7m (loss widened by 288% from...

Yahoo | November 11, 2022

Insiders own 35% of XBiotech Inc. (NASDAQ:XBIT) shares but individual investors control 47% of the company

If you want to know who really controls XBiotech Inc. ( NASDAQ:XBIT ), then you'll have to look at the makeup of its...

Yahoo | October 31, 2022

XBiotech Announces First Patient Enrolled into the French National Cancer Institute (INCA) Sponsored Phase I/II/III Clinical Study for Natrunix™ Therapy for Colorectal Cancer

INCA funded Phase I/II/III Study for Natrunix in Combination with Trifluridine/Tipiracil, the TASKIN Study, Launches at 20 Leading Medical Centers in FranceAUSTIN, Texas, Oct. 13, 2022 (GLOBE NEWSWIRE) -- XBiotech (NASDAQ: XBIT) announced today the enrollment of the first patient in a multicenter, randomized clinical study for Natrunix in combination with trifluridine/tipiracil for the treatment of colorectal cancer. The much anticipated clinical study for XBiotech’s candidate cancer treatment i

Yahoo | October 13, 2022

XBiotech (NASDAQ:XBIT) shareholders have endured a 73% loss from investing in the stock a year ago

As every investor would know, you don't hit a homerun every time you swing. But it would be foolish to simply accept...

Yahoo | September 8, 2022

We Think XBiotech (NASDAQ:XBIT) Can Afford To Drive Business Growth

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Yahoo | August 12, 2022

Read More 'XBIT' Stories Here

XBIT Price Returns

1-mo -13.11%
3-mo -23.94%
6-mo -48.91%
1-year -75.83%
3-year -73.46%
5-year -26.33%
YTD -72.60%
2021 -28.88%
2020 -16.15%
2019 267.42%
2018 28.93%
2017 -61.07%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!

Page generated in 0.7756 seconds.